PAP
INO icon

Persistent Asset Partners’s Inovio Pharmaceuticals INO Stock Holding History

Persistent Asset Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Buy
701
+511
+269% +$606 0.01% 597
2026
Q1 		$8.55K Sell
190
-77
-29% -$127 ﹤0.01% 289
2025
Q4 		$7.5K Buy
+267
New +$588 ﹤0.01% 329

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Persistent Asset Partners's INO Position: Q2 2026 in Review

Persistent Asset Partners sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 142,164 shares — an estimated $169K sold.

Persistent Asset Partners first reported a position in INO in Q4 2025 and held it in 2 quarters. The position peaked at $247K in Q1 2026. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Persistent Asset Partners reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 142,164 Inovio Pharmaceuticals shares in Q2 2026, an estimated $169K.
  • Persistent Asset Partners first reported a position in Inovio Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Inovio Pharmaceuticals position peaked at $247K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.